Search company, investor...

Predict your next investment

Eli Lilly and Company company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
lilly.com

Investments

109

Portfolio Exits

28

Funds

2

Partners & Customers

10

Service Providers

3

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a drug firm that focuses on neuroscience, endocrinology, cancer, and immunology. Its key products include Verzenio for cancer, Jardiance, Trulicity, Humalog, and Humulin for diabetes, and Taltz and Olumiant for immunology. The company was founded in 1876 and is based in Indianapolis, Indiana.

Headquarters Location

Lilly Corporate Center

Indianapolis, Indiana, 46285,

United States

800-545-5979

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Expert Collections containing Eli Lilly and Company

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Eli Lilly and Company in 1 Expert Collection, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

Latest Eli Lilly and Company News

EU drug regulator to review Lilly's Mounjaro in multi-dose pen

Feb 19, 2024

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (46.6%): products for treating osteoporosis, diabetes, and growth problems; - oncology (20.3%); - immunology diseases (11.8%); - neurology (6.7%): primarily drugs used in treating depression and schizophrenia; - other (14.6%). Net sales are distributed geographically as follows: the United States (59.4%), Europe (16.9%), Japan (8.3%), China (5.9%) and other (9.5%). Sector

Eli Lilly and Company Investments

109 Investments

Eli Lilly and Company has made 109 investments. Their latest investment was in FireflyBio as part of their Series A on February 15, 2024.

CBI Logo

Eli Lilly and Company Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/15/2024

Series A

FireflyBio

$94M

Yes

3

1/24/2024

Series C - VI

PRISM BioLab

$10.3M

Yes

2

1/5/2024

Seed VC

UpDoc

Yes

2

12/7/2023

Private Equity - III

Subscribe to see more

Subscribe to see more

10

11/21/2023

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/15/2024

1/24/2024

1/5/2024

12/7/2023

11/21/2023

Round

Series A

Series C - VI

Seed VC

Private Equity - III

Series C

Company

FireflyBio

PRISM BioLab

UpDoc

Subscribe to see more

Subscribe to see more

Amount

$94M

$10.3M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

2

2

10

10

Eli Lilly and Company Portfolio Exits

28 Portfolio Exits

Eli Lilly and Company has 28 portfolio exits. Their latest portfolio exit was Alto Neuroscience on February 02, 2024.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/2/2024

IPO

$99M

Public

2

7/17/2023

Acquired

$99M

6

1/3/2023

Merger

$99M

1

12/28/2021

Take Private

Subscribe to see more

$99M

Subscribe to see more

10

5/28/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/2/2024

7/17/2023

1/3/2023

12/28/2021

5/28/2021

Exit

IPO

Acquired

Merger

Take Private

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

2

6

1

10

10

Eli Lilly and Company Acquisitions

30 Acquisitions

Eli Lilly and Company acquired 30 companies. Their latest acquisition was POINT Biopharma on December 27, 2023.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/27/2023

Series A

$99M

$20M

Acq - P2P

7

10/17/2023

Series A

$99M

$35.62M

Acquired

2

8/11/2023

Series B

$99M

$103.8M

Acq - P2P

7

8/9/2023

Series C

Subscribe to see more

$99M

$99M

Subscribe to see more

10

7/14/2023

Series A

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

12/27/2023

10/17/2023

8/11/2023

8/9/2023

7/14/2023

Investment Stage

Series A

Series A

Series B

Series C

Series A

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$20M

$35.62M

$103.8M

$99M

$99M

Note

Acq - P2P

Acquired

Acq - P2P

Subscribe to see more

Subscribe to see more

Sources

7

2

7

10

10

Eli Lilly and Company Fund History

2 Fund Histories

Eli Lilly and Company has 2 funds, including Social Impact Venture Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Social Impact Venture Fund

1

Australia Biotech Fund

Subscribe to see more

Subscribe to see more

10

Closing Date

Fund

Social Impact Venture Fund

Australia Biotech Fund

Fund Type

Subscribe to see more

Status

Subscribe to see more

Amount

Sources

1

10

Eli Lilly and Company Partners & Customers

10 Partners and customers

Eli Lilly and Company has 10 strategic partners and customers. Eli Lilly and Company recently partnered with Isomorphic Laboratories on January 1, 2024.

Date

Type

Business Partner

Country

News Snippet

Sources

1/8/2024

Licensor

United Kingdom

Published: Jan 08, 2024By Tristan Manalac. Lilly, Novartis Sign AI Partnership with Alphabet’s Isomorphic.

Last week , Boehringer Ingelheim inked a $ 2 billion siRNA contract with Ribo , Novo dropped $ 1 billion in separate research partnerships with two Flagship companies and AbbVie pledged up to $ 1.44 billion for two CAR-T deals with Umoja .

1

1/7/2024

Vendor

United Kingdom

AI drug discovery startup Isomorphic Labs partners with Eli Lilly and Novartis

London-based Isomorphic Labs Ltd. , a drug discovery-focused artificial intelligence startup that was spun out of Google LLC 's DeepMind unit just over two years ago , has announced key partnerships with two of the world 's biggest pharmaceutical companies -- Eli Lilly and Novartis AG .

3

1/4/2024

Distributor

United States

1

1/2/2024

Licensor

China

Subscribe to see more

Subscribe to see more

10

12/21/2023

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

1/8/2024

1/7/2024

1/4/2024

1/2/2024

12/21/2023

Type

Licensor

Vendor

Distributor

Licensor

Partner

Business Partner

Country

United Kingdom

United Kingdom

United States

China

United States

News Snippet

Published: Jan 08, 2024By Tristan Manalac. Lilly, Novartis Sign AI Partnership with Alphabet’s Isomorphic.

Last week , Boehringer Ingelheim inked a $ 2 billion siRNA contract with Ribo , Novo dropped $ 1 billion in separate research partnerships with two Flagship companies and AbbVie pledged up to $ 1.44 billion for two CAR-T deals with Umoja .

AI drug discovery startup Isomorphic Labs partners with Eli Lilly and Novartis

London-based Isomorphic Labs Ltd. , a drug discovery-focused artificial intelligence startup that was spun out of Google LLC 's DeepMind unit just over two years ago , has announced key partnerships with two of the world 's biggest pharmaceutical companies -- Eli Lilly and Novartis AG .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

3

1

10

10

Eli Lilly and Company Service Providers

4 Service Providers

Eli Lilly and Company has 4 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Other

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acq - P2P

Subscribe to see more

Subscribe to see more

Provider Type

Other

Subscribe to see more

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Eli Lilly and Company Team

68 Team Members

Eli Lilly and Company has 68 team members, including current Chief Executive Officer, David Ricks.

Name

Work History

Title

Status

David Ricks

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

David Ricks

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Eli Lilly and Company to Competitors

B
Boehringer Ingelheim

Boehringer Ingelheim operates as a biopharmaceutical company. The company's main offerings include therapies in areas of high unmet medical need, spanning three business areas such as human pharma, animal health, and biopharmaceutical contract manufacturing. It primarily serves the pharmaceutical and healthcare industries. The company was founded in 1885 and is based in Ingelheim am Rhein, Germany.

G
GAIA

GAIA develops digital therapy solutions that offer physicians, therapists, payers, and patients the same effect sizes, similar safety profiles, and equal levels of convenience as found in well-developed, pharmaceutical solutions. Its product lines include Velibra, a platform for excessive fears and worries; Elevida, an online program for people with MS fatigue; Deprexis, an online platform for people with depression; Vorvida, a tool to reduce alcohol consumption; Optimune, offering digital therapy for breast cancer; and Levidex, a companion for multiple sclerosis. The company was founded in 1997 and is based in Hamburg, Germany.

Sumitovant Logo
Sumitovant

Sumitovant is a technology-driven biopharmaceutical company that focuses on the development and commercialization of novel therapies. The company's main offerings include the development of treatments for patients with rare conditions and other diseases, utilizing their proprietary computing and data platforms and scientific expertise. These treatments address unmet needs in various areas such as pediatrics, urology, oncology, women's health, specialty respiratory, and infectious diseases. It was founded in 2019 and is based in New York, New York. Sumitovant operates as a subsidiary of Sumitomo Dainippon Pharma.

E
Enveda Biosciences

Enveda Biosciences operates a biotechnology company. It builds a high-resolution chemical map of the natural world to tackle the toughest problems in drug discovery. Its solution integrates multiple data streams to nominate therapeutic hypotheses, target candidates, and mechanisms of action. It was formerly known as Enveda Therapeutics. The company was founded in 2019 and is based in Boulder, Colorado.

M
MS Lounge

MS Lounge is an information platform focused on multiple sclerosis within the healthcare sector. The platform provides educational content about multiple sclerosis, its symptoms, daily life management, and social support systems for patients and their families. It also offers guidance on the use of specific medical drugs for treating multiple sclerosis. It is based in Chuo-ku, Japan.

Vida Health Logo
Vida Health

Vida Health provides personalized health coaching and programs in the healthcare sector. The company offers services for managing chronic conditions such as diabetes, obesity, depression, and hypertension through a combination of human-led care and technology. Vida Health primarily sells to employers and health plans, providing solutions to support employee benefits and physical and mental health care. It was founded in 2014 and is based in San Francisco, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.